News | April 25, 2023
Boehringer Ingelheim inaugurates largest European development centre for biotechnology
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
EC grants conditional marketing authorization based on the EFFISAYIL trial
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Biopharma and CROs to benefit from simplified access to global research sites
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Subscribe To Our Newsletter & Stay Updated
